Bosi Emanuele Professore ordinarioMedicinaSSD MED/09 – Medicina Interna; SC 06/B1 – Medicina Interna; MSC 06/D – Clinica medica generale

Biografia

Pubblicazioni

English version

Biografia

Luogo e Data di Nascita: Milano, 13 Marzo 1954

Posizione Accademica:

Professore Ordinario di Endocrinologia, Università Vita- Salute San Raffaele, Milano

Posizione Ospedaliera:

Primario, Unità Operativa di Medicina Generale a indirizzo diabetologico ed endocrino-metabolico, Ospedale San Raffaele, Milano;

Posizione di Ricerca:

Director, Diabetes Research Institute, Istituto Scientifico (IRCCS) San Raffaele, Milano;

Titoli:

Laurea in Medicina e Chirurgia, Università di Milano, 1979;

Specializzazione in Diabetologia e Malattie del Ricambio, Università di Milano, 1983;

Specializzazione in Allergologia e Immunologia Clinica, Università di Milano, 1987;

Professore Associato in Medicina Interna, Concorso Nazionale, 1992;

Professore Ordinario di Endocrinologia, Concorso di Idoneità Nazionale, 2014.

Training:

1982-83 Hôpital Herriot, Lione, Assistente Universitario Straniero, disciplina trapianto di pancreas;

1984-85 Istituto San Raffaele, Milano, Assistente Ricercatore, disciplina Diabetologia;

1986-87 Middlesex Hospital & St. Bartholomew’s Hospital, Londra, Research Associate, disciplina immunologia del diabete e delle endocrinopatie;

Pubblicazioni

Pubblicazioni selezionate (dal 2011)

Gandolfi A, Pontara A, Di Terlizzi G, Rizzo N, Nicoletti R, Scavini M, Galimberti G, Bosi E. Improvement in clinical symptoms of scleredema diabeticorum by frequency-modulated electromagnetic neural stimulation: a case report. Diabetes Care 2014;37:e233-4

Aronson R, Gottlieb PA, Christiansen JS, Donner TW, Bosi E, Bode BW, Pozzilli P; for the DEFEND Investigator Group. Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes. Diabetes Care 2014;37:2746-54

Lampasona V, Passerini L, Barzaghi F, Lombardoni C, Bazzigaluppi E, Brigatti C, Bacchetta R, Bosi E. Autoantibodies to harmonin and villin are diagnostic markers in children with IPEX syndrome. PLoS One. 2013;8:e78664

Bosi E, Scavini M, Ceriello A, Cucinotta D, Tiengo A, Marino R, Bonizzoni E, Giorgino F; PRISMA Study Group. Intensive Structured Self-Monitoring of Blood Glucose and Glycemic Control in Noninsulin-Treated Type 2 Diabetes: The PRISMA randomized trial. Diabetes Care 2013; 36:2887-94

Valle A, Giamporcaro GM, Scavini M, Stabilini A, Grogan P, Bianconi E, Sebastiani G, Masini M, Maugeri N, Porretti L, Bonfanti R, Meschi F, De Pellegrin M, Lesma A, Rossini S, Piemonti L, Marchetti P, Dotta F, Bosi E, Battaglia M. Reduced circulating neutrophils precedes and accompanies type 1 diabetes. Diabetes 2013;62:2072-7.

Bosi E, Bax G, Scionti L, Spallone V, Tesfaye S, Valensi P, Ziegler D. Frequency-modulated electromagnetic neural stimulation (FREMS) as a treatment for symptomatic diabetic neuropathy: results from a double-blind, randomised, multicentre, long-term, placebo-controlled clinical trial. Diabetologia 2013;56:467-75

Piemonti L, Everly MJ, Maffi P, Scavini M, Poli F, Nano R, Cardillo M, Melzi R, Mercalli A, Sordi V, Lampasona V, Espadas de Arias A, Scalamogna M, Bosi E, Bonifacio E, Secchi A, Terasaki PI. Alloantibody and Autoantibody Monitoring Predicts Islet Transplantation Outcome in Human Type 1 Diabetes. Diabetes 2013;62:1656-64.

Mercalli A, Lampasona V, Klingel K, Albarello L, Lombardoni C, Ekström J, Sordi V, Bolla A, Mariani A, Bzhalava D, Dillner J, Roivainen M, Bosi E, Piemonti L. No evidence of enteroviruses in the intestine of patients with type 1 diabetes. Diabetologia 2012;55:2479-88

Davalli AM, Perego C, Folli FB, Bosi E. Long lasting remission of type 1 diabetes following treatment with topiramate for generalized seizures. Acta Diabetol 49: 75-79, 2012

Laurenzi A, Bolla AM, Panigoni G, Doria V, Uccellatore A, Peretti E, Saibene A, Galimberti G, Bosi E, Scavini M. Effects of Carbohydrate Counting on Glucose Control and Quality of Life Over 24 Weeks in Adult Patients With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion: A randomized, prospective clinical trial (GIOCAR). Diabetes Care 34: 823-827, 2011

Badami E, Sorini C, Coccia M, Usuelli V, Molteni L, Bolla AM, Scavini M, Mariani A, King C, Bosi E, Falcone M. Defective Differentiation of Regulatory FoxP3+ T Cells by Small-Intestinal Dendritic Cells in Patients With Type 1 diabetes. Diabetes 60: 2120-2124, 2011

Bosi E, Ellis GC, Wilson CA, Fleck PR. Alogliptin as a Third Oral Antidiabetic Drug in Patients With Type 2 Diabetes and Inadequate Glycemic Control on Metformin and Pioglitazone: A 52-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study. Diabetes Obes Metab 13: 1088-1096, 2011

Occhipinti M, Lampasona V, Vistoli F, Bazzigaluppi E, Scavini M, Boggi U, Marchetti P, Bosi E.Zinc transporter 8 autoantibodies increase the predictive value of islet autoantibodies for function loss of technically successful solitary pancreas transplant. Transplantation 92: 674-677, 2011

Ahrén B, Foley JE, Bosi E. Clinical evidence and mechanistic basis for vildagliptin’s action when added to metformin. Diabetes Obes Metab 13: 193-203, 2011

 

Letture e seminari su invite (dal 2014)

‘Revisione critica dei recent RCTs: SAVOR-TIMI e EXAMINE’. Costruzione della evidence-based medicine in diabetologia. Corso della Società Italiana di Diabetologia, Ospedale Maggiore Policlinico, Milano, 7 Febbraio 2014

‘Modern approaches to the management of type 2 diabetes: optimizing patient care’. Seminars at: Dubai Diabetes Center, Dubai, 19 February 2014; Grand Millennium, Al Whada, Abu Dhabi, 19 February 2014; Imperial College Physicians, Grand Hyatt, Dubai, 21 February 2014

‘Do we Still Need Tight Glycemic Control in Type 2 Diabetes?’. Plenary lecture, 4th Emirates Diabetes & Endocrine Congress. Grand Hyatt Conference & Convention Centre, Dubai, 20 February 2014

‘The Role of Insulin Therapy: When Do We Decide to Give it and How?’. Interactive workshop, 4th Emirates Diabetes & Endocrine Congress. Grand Hyatt Conference & Convention Centre, Dubai, 20 February 2014

‘Modern approaches to the management of type 2 diabetes: optimizing patient care’. Novartis Symposium, 4th Emirates Diabetes & Endocrine Congress. Grand Hyatt Conference & Convention Centre, Dubai, 21 February 2014

Challenges in diabetes management: evolving targets and therapeutics’ andKey safety considerations for DPP4 inhibitors: focus on vildagliptin. Novartis AMAC Diabetes Speaker Masterclass Meeting, Hotel Intercontinental Dubai Festival City, Dubai, 28 February-1 March 2014

‘Galvus®/Eucreas® as a therapeutic option in type 2 diabetes: What is the evidence?’. Novartis Region Europe Speaker Masterclass, Hotel California Champs Elysées, Paris, 27 March, 2014

Structured SMBG in the management of type 2 diabetes’. Programa de excelencia en diabetes. International Exchange course. Hotel Vincci Soho, Madrid, 28 March 2014

‘Strategies for the initial treatment of Diabetes mellitus: an approach with the goal to crack insulin-resistance’ and ‘Non pharmacological and pharmacological options: what is the evidence so far? Pre-diabetes and new onset diabetes: diabetologist perspective’. Berlin Chemie Diabetes Master-Class Project, Hilton Hotel, Sofia, 29 March 2014

‘Le insuline basali iniettabili di oggi e di domani: le opzioni aumenteranno da 5 a 7. Come orientarsi nel diabete di tipo 1 e tipo 2?’. XII Corso di Alta Formazione in Diabetologia. Hotel Giò, Perugia, 30 Marzo 2014

‘Flash Glucose Monitoring Technology from the clinician point of view’. Abbott FreeStyle Libre Kick Off Meeting. Hilton Diagonal Mar, Barcelona, 25 August 2014

TrialNet in the world and at the San Raffaele’. Diabetes Research Institute Seminars, San Raffaele Scientific Institute, Milan, 11 September 2014

Restoring blood glucose to normal values: importance for the progression of the disease’. Berlin Chemie EASD satellite meeting: New insights in and controversies about type 2 diabetes. Palais Ferstel, Vienna, 16 September 2014

‘Consensus recommendations for the use of ambulatory glucose profile in clinical practice’. Flash Glucose Monitoring System Expert Meeting, Abbott Diabetes Care Center, Witney, Oxfordshire, 23 September 2014

Rational basis and clinical results of Alogliptin and Pioglitazone association’. Takeda Pharmaceuticals Korea, Annual Business Meeting, The Westin Chosun Hotel, Busan, 26 September 2014

Current updates on incretin-based therapy and emerging approaches in diabetes care’. The RED (Recent Evidences in Diabetes) Symposium, The Westin Chosun Hotel, Busan, 27 September 2014

‘Treat to target: il modello del diabete’. Giornate reumatologiche d’autunno, Ospedale Santa Chiara di Trento, 2 Ottobre 2014

I nuovi farmaci. Quale miglioramento? La rivoluzione del GLP-1’. IV Giornate Diabetologiche Luinesi, Centro Congressi Villa Cagnola, Gazzada Schianno, 11 Ottobre 2014

‘Il mito dell’ansa chiusa’. Società Italiana di Diabetologia – VII Giornate Diabetologiche Sorrentine: dalla fisiopatologia alla gestione del paziente. Hilton Sorrento Palace, Sorrento, 18 Ottobre 2014

‘Nuove prospettive terapeutiche nel diabete di tipo 2‘. Workshop – I bisogni insoddisfatti delle persone con diabete. Ospedale San Raffaele, Milano, 25 Ottobre 2014

‘Screening e Prevenzione del Diabete di Tipo 1’. Convegno, Milano Tipo UNO, Hotel Hilton Milan, Milano, 30 Ottobre 2014

‘Le Innovazioni Terapeutiche nella cura del Diabete di Tipo 1’. 2° Evento Brescia Diabete, Villa Fenaroli Palace Hotel , Rezzato (BS), 7 Novembre 2014

The Different Masks of Diabetes: focus on the adult autoimmune diabetes’. All-Russian Endocrinology Research Center, Moscow, 12 November 2014

The Different Masks of Diabetes: focus on the adult autoimmune diabetes’. Annual School of Endocrinologists, Hotel Crowne Plaza St. Petersburg Airport, St. Petersburg, 14 November 2014

‘Monitoraggio della Glicemia nel diabete di tipo 2 in terapia non insulinica: PRO’. Convegno SID Lombardia: Monitoraggio della Glicemia nel XXI Secolo, Policlinico di Monza, Monza, 11 Dicembre 2014

English version

Place and date of birth: Milan, 13 March 1954

Academic position: Professor of Endocrinology, Vita-Salute San Raffaele University, Milan;

Hospital Position: Head, General Medicine, Diabetes & Endocrinology Unit, San Raffaele Hospital, Milan;

Research Position: Director, Diabetes Research Institute, San Raffaele Scientific Institute, Milan;

 

Degrees:

M.D., University of Milan, 1979;

Specialist Diploma in Diabetology and Metabolic Diseases, University of Milan, 1983;

Specialist Diploma in Allergology and Clinical Immunology, University of Milan, 1987;

Associate Professor of Internal Medicine, National Appointment Competition Call, 1992;

Full Professor of Endocrinology, National Eligibility Competition Call, 2014.

 

Training:

1982-83 Hôpital Herriot, Lyon, Foreign University Assistant, field: pancreas transplantation;

1984-85 San Raffaele Institute, Milan, Research Assistant, field: diabetes;

1986-87 Middlesex Hospital & St. Bartholomew’s Hospital, London, Research Associate; field autoimmunity in diabetes and endocrine diseases;

Publications: Author or coauthor in more than 150 publications.

Main Research Grants (since 2008):

– Director, JDRF (Juvenile Diabetes Research Foundation, USA) International Site, 2015-2017 ($ 300,000)

– Director, TrialNet International Clinical Center (NIDDK- National Institutes of Health, USA), 2003 to date ($2,083,335, as December 2014)

– Director, JDRF (Juvenile Diabetes Research Foundation, USA) International Site, 2012-2014 ($ 214,500)
– Director, JDRF (Juvenile Diabetes Research Foundation, USA) International Site, 2009-2011 ($ 214,500)
– Principal Investigator, FORISID (Italian Diabetes Society Research Foundation) Research Grant: Gut immune regulation in patients with type 1 Diabetes, 2010 (€ 50,000)
– Director, JDRF (Juvenile Diabetes Research Foundation, USA) Italy/Germany TrialNet International Clinical Center, 2003-2008 ($ 301,000)
Selected publications (since 2011)

Gandolfi A, Pontara A, Di Terlizzi G, Rizzo N, Nicoletti R, Scavini M, Galimberti G, Bosi E. Improvement in clinical symptoms of scleredema diabeticorum by frequency-modulated electromagnetic neural stimulation: a case report. Diabetes Care 2014;37:e233-4

Aronson R, Gottlieb PA, Christiansen JS, Donner TW, Bosi E, Bode BW, Pozzilli P; for the DEFEND Investigator Group. Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes. Diabetes Care 2014;37:2746-54

Lampasona V, Passerini L, Barzaghi F, Lombardoni C, Bazzigaluppi E, Brigatti C, Bacchetta R, Bosi E. Autoantibodies to harmonin and villin are diagnostic markers in children with IPEX syndrome. PLoS One. 2013;8:e78664

Bosi E, Scavini M, Ceriello A, Cucinotta D, Tiengo A, Marino R, Bonizzoni E, Giorgino F; PRISMA Study Group. Intensive Structured Self-Monitoring of Blood Glucose and Glycemic Control in Noninsulin-Treated Type 2 Diabetes: The PRISMA randomized trial. Diabetes Care 2013; 36:2887-94

Valle A, Giamporcaro GM, Scavini M, Stabilini A, Grogan P, Bianconi E, Sebastiani G, Masini M, Maugeri N, Porretti L, Bonfanti R, Meschi F, De Pellegrin M, Lesma A, Rossini S, Piemonti L, Marchetti P, Dotta F, Bosi E, Battaglia M. Reduced circulating neutrophils precedes and accompanies type 1 diabetes. Diabetes 2013;62:2072-7.

Bosi E, Bax G, Scionti L, Spallone V, Tesfaye S, Valensi P, Ziegler D. Frequency-modulated electromagnetic neural stimulation (FREMS) as a treatment for symptomatic diabetic neuropathy: results from a double-blind, randomised, multicentre, long-term, placebo-controlled clinical trial. Diabetologia 2013;56:467-75

Piemonti L, Everly MJ, Maffi P, Scavini M, Poli F, Nano R, Cardillo M, Melzi R, Mercalli A, Sordi V, Lampasona V, Espadas de Arias A, Scalamogna M, Bosi E, Bonifacio E, Secchi A, Terasaki PI. Alloantibody and Autoantibody Monitoring Predicts Islet Transplantation Outcome in Human Type 1 Diabetes. Diabetes 2013;62:1656-64.

Mercalli A, Lampasona V, Klingel K, Albarello L, Lombardoni C, Ekström J, Sordi V, Bolla A, Mariani A, Bzhalava D, Dillner J, Roivainen M, Bosi E, Piemonti L. No evidence of enteroviruses in the intestine of patients with type 1 diabetes. Diabetologia 2012;55:2479-88

Davalli AM, Perego C, Folli FB, Bosi E. Long lasting remission of type 1 diabetes following treatment with topiramate for generalized seizures. Acta Diabetol 49: 75-79, 2012

Laurenzi A, Bolla AM, Panigoni G, Doria V, Uccellatore A, Peretti E, Saibene A, Galimberti G, Bosi E, Scavini M. Effects of Carbohydrate Counting on Glucose Control and Quality of Life Over 24 Weeks in Adult Patients With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion: A randomized, prospective clinical trial (GIOCAR). Diabetes Care 34: 823-827, 2011

Badami E, Sorini C, Coccia M, Usuelli V, Molteni L, Bolla AM, Scavini M, Mariani A, King C, Bosi E, Falcone M. Defective Differentiation of Regulatory FoxP3+ T Cells by Small-Intestinal Dendritic Cells in Patients With Type 1 diabetes. Diabetes 60: 2120-2124, 2011

Bosi E, Ellis GC, Wilson CA, Fleck PR. Alogliptin as a Third Oral Antidiabetic Drug in Patients With Type 2 Diabetes and Inadequate Glycemic Control on Metformin and Pioglitazone: A 52-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study. Diabetes Obes Metab 13: 1088-1096, 2011

Occhipinti M, Lampasona V, Vistoli F, Bazzigaluppi E, Scavini M, Boggi U, Marchetti P, Bosi E.Zinc transporter 8 autoantibodies increase the predictive value of islet autoantibodies for function loss of technically successful solitary pancreas transplant. Transplantation 92: 674-677, 2011

Ahrén B, Foley JE, Bosi E. Clinical evidence and mechanistic basis for vildagliptin’s action when added to metformin. Diabetes Obes Metab 13: 193-203, 2011

Invited lectures and seminars (since 2014)

‘Revisione critica dei recent RCTs: SAVOR-TIMI e EXAMINE’. Costruzione della evidence-based medicine in diabetologia. Corso della Società Italiana di Diabetologia, Ospedale Maggiore Policlinico, Milano, 7 Febbraio 2014

‘Modern approaches to the management of type 2 diabetes: optimizing patient care’. Seminars at: Dubai Diabetes Center, Dubai, 19 February 2014; Grand Millennium, Al Whada, Abu Dhabi, 19 February 2014; Imperial College Physicians, Grand Hyatt, Dubai, 21 February 2014

‘Do we Still Need Tight Glycemic Control in Type 2 Diabetes?’. Plenary lecture, 4th Emirates Diabetes & Endocrine Congress. Grand Hyatt Conference & Convention Centre, Dubai, 20 February 2014

‘The Role of Insulin Therapy: When Do We Decide to Give it and How?’. Interactive workshop, 4th Emirates Diabetes & Endocrine Congress. Grand Hyatt Conference & Convention Centre, Dubai, 20 February 2014

‘Modern approaches to the management of type 2 diabetes: optimizing patient care’. Novartis Symposium, 4th Emirates Diabetes & Endocrine Congress. Grand Hyatt Conference & Convention Centre, Dubai, 21 February 2014

Challenges in diabetes management: evolving targets and therapeutics’ andKey safety considerations for DPP4 inhibitors: focus on vildagliptin. Novartis AMAC Diabetes Speaker Masterclass Meeting, Hotel Intercontinental Dubai Festival City, Dubai, 28 February-1 March 2014

‘Galvus®/Eucreas® as a therapeutic option in type 2 diabetes: What is the evidence?’. Novartis Region Europe Speaker Masterclass, Hotel California Champs Elysées, Paris, 27 March, 2014

Structured SMBG in the management of type 2 diabetes’. Programa de excelencia en diabetes. International Exchange course. Hotel Vincci Soho, Madrid, 28 March 2014

‘Strategies for the initial treatment of Diabetes mellitus: an approach with the goal to crack insulin-resistance’ and ‘Non pharmacological and pharmacological options: what is the evidence so far? Pre-diabetes and new onset diabetes: diabetologist perspective’. Berlin Chemie Diabetes Master-Class Project, Hilton Hotel, Sofia, 29 March 2014

‘Le insuline basali iniettabili di oggi e di domani: le opzioni aumenteranno da 5 a 7. Come orientarsi nel diabete di tipo 1 e tipo 2?’. XII Corso di Alta Formazione in Diabetologia. Hotel Giò, Perugia, 30 Marzo 2014

‘Flash Glucose Monitoring Technology from the clinician point of view’. Abbott FreeStyle Libre Kick Off Meeting. Hilton Diagonal Mar, Barcelona, 25 August 2014

TrialNet in the world and at the San Raffaele’. Diabetes Research Institute Seminars, San Raffaele Scientific Institute, Milan, 11 September 2014

Restoring blood glucose to normal values: importance for the progression of the disease’. Berlin Chemie EASD satellite meeting: New insights in and controversies about type 2 diabetes. Palais Ferstel, Vienna, 16 September 2014

‘Consensus recommendations for the use of ambulatory glucose profile in clinical practice’. Flash Glucose Monitoring System Expert Meeting, Abbott Diabetes Care Center, Witney, Oxfordshire, 23 September 2014

Rational basis and clinical results of Alogliptin and Pioglitazone association’. Takeda Pharmaceuticals Korea, Annual Business Meeting, The Westin Chosun Hotel, Busan, 26 September 2014

Current updates on incretin-based therapy and emerging approaches in diabetes care’. The RED (Recent Evidences in Diabetes) Symposium, The Westin Chosun Hotel, Busan, 27 September 2014

‘Treat to target: il modello del diabete’. Giornate reumatologiche d’autunno, Ospedale Santa Chiara di Trento, 2 Ottobre 2014

I nuovi farmaci. Quale miglioramento? La rivoluzione del GLP-1’. IV Giornate Diabetologiche Luinesi, Centro Congressi Villa Cagnola, Gazzada Schianno, 11 Ottobre 2014

‘Il mito dell’ansa chiusa’. Società Italiana di Diabetologia – VII Giornate Diabetologiche Sorrentine: dalla fisiopatologia alla gestione del paziente. Hilton Sorrento Palace, Sorrento, 18 Ottobre 2014

‘Nuove prospettive terapeutiche nel diabete di tipo 2‘. Workshop – I bisogni insoddisfatti delle persone con diabete. Ospedale San Raffaele, Milano, 25 Ottobre 2014

‘Screening e Prevenzione del Diabete di Tipo 1’. Convegno, Milano Tipo UNO, Hotel Hilton Milan, Milano, 30 Ottobre 2014

‘Le Innovazioni Terapeutiche nella cura del Diabete di Tipo 1’. 2° Evento Brescia Diabete, Villa Fenaroli Palace Hotel , Rezzato (BS), 7 Novembre 2014

The Different Masks of Diabetes: focus on the adult autoimmune diabetes’. All-Russian Endocrinology Research Center, Moscow, 12 November 2014

The Different Masks of Diabetes: focus on the adult autoimmune diabetes’. Annual School of Endocrinologists, Hotel Crowne Plaza St. Petersburg Airport, St. Petersburg, 14 November 2014

‘Monitoraggio della Glicemia nel diabete di tipo 2 in terapia non insulinica: PRO’. Convegno SID Lombardia: Monitoraggio della Glicemia nel XXI Secolo, Policlinico di Monza, Monza, 11 Dicembre 2014

Il titolare del presente curriculum vitae, pubblicato online sul portale www.unisr.it, è garante in via esclusiva della correttezza e della veridicità dei dati e delle informazioni in esso riportate e del loro eventuale e puntuale aggiornamento. Egli è dunque il diretto ed unico responsabile dei contenuti indicati nei propri curricula.